Clinical trials: B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
B-NHL, B-Non Hodgkin Lymphoma
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
Background: Acute lymphoblastic leukemia (ALL) is the most common cancer in children. About 90% of children and young adults who are treated for ALL can now be cured.
- Conditions
- B-NHL, B-Non Hodgkin Lymphoma, Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia
- Trial name
- NCT05442515
- Testing
- CD19/CD22-CAR-transduced T cells, cyclophosphamide, fludarabine
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- National Cancer Institute (NCI)
Cachexia, Lymphoma
Celecoxib in Managing Pain, Weight Loss, and Weakness in Patients With Advanced Cancer
RATIONALE: Celecoxib may help relieve moderate or severe pain associated with cancer. It may also decrease weight loss and improve muscle strength in cancer patients.
- Conditions
- Cachexia, Lymphoma, Melanoma (Skin), Ovarian Cancer
- Trial name
- NCT00093678
- Testing
- celecoxib, anticachectic therapy, nutritional support
- Sponsor
- Eastern Cooperative Oncology Group
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia
Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation
This is a phase I single center dose escalation study with an extension at the best available dose to determine the tolerability of inducible regulatory T cells (iTregs) when given to adult patients undergoing non-myeloablative…
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Non-Hodgkin Lymphoma
- Trial name
- NCT01634217
- Testing
- iTreg
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Lymphoma
Combination Chemotherapy With or Without Etoposide in Treating Older Patients With Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00060385
- Testing
- CHOP regimen, EPOCH regimen, cyclophosphamide
- Where
- Belgium
- Volunteers
- 3 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia
Monoclonal Antibodies in Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) (MARALL)
The treatment of adult B-cell acute lymphoblastic leukaemia (ALL) has progressed considerably in the past 3 decades, particularly due to intensification of chemotherapies, improved supportive care and the incorporation of stem…
- Trial name
- MARALL (NCT01279707)
- Testing
- humanised monoclonal antibody, veltuzumab, humanised monoclonal antibody epratuzumab, humanised monoclonal antibodies veltuzumab and epratuzumab
- Where
- 10 sites in United Kingdom
- Volunteers
- 55 people
- Sponsor
- Queen Mary University of London
Double Cord Blood Transplant, Acute Myelogenous Leukemia
TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation
The purpose of this study is to evaluate the effect of TXA127 on neutrophil and platelet counts in adult patients who have undergone a double cord blood transplant.
- Conditions
- Double Cord Blood Transplant, Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Myelofibrosis
- Trial name
- USBTXA127CBT (NCT01300611)
- Testing
- TXA127 300 mcg/kg/day, TXA127 1000 mcg/kg/day
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Tarix Pharmaceuticals
Breast Cancer, Leukemia
Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy.
- Conditions
- Breast Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00006225
- Testing
- filgrastim, recombinant flt3 ligand, recombinant human thrombopoietin
- Where
- United States
- Sponsor
- Northwestern University
Acute Lymphocytic Leukemia, Diffuse Large Cell Lymphoma
Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy
This is a pilot study to evaluate humanized CD19 redirected autologous T cells (or huCART19 cells) in patients with relapsed or refractory CD19+ leukemia and lymphoma that was previously treated with cell therapy.
- Trial name
- NCT02374333
- Testing
- huCART19
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- University of Pennsylvania
Hematologic Neoplasm, HIV Infection
Stem Cell (Modified Bone Marrow) Transplantation in HIV-Infected Patients With Blood Cancer
This study will investigate the safety and effectiveness of a new stem cell transplant procedure to treat acute or chronic leukemia, multiple myeloma, myelodysplastic syndrome, Hodgkin's and non-Hodgkin's lymphoma in HIV-infected…
- Trial name
- NCT00005785
- Testing
- GCSF Mobilized Allogeneic PBSC Cultured w/Cytokines; Transduced w/RV
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia
Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction
Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Phase I trial to study the effectiveness of imatinib mesylate in treating patients who have advanced cancer and liver…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Primary CNS Lymphoma
- Trial name
- NCT00025415
- Testing
- imatinib mesylate, pharmacological study
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant
RATIONALE: Antiemetic drugs, such as aprepitant, ondansetron, and dexamethasone, may help lessen or prevent nausea and vomiting in patients undergoing a stem cell transplant.
- Trial name
- NCT00248547
- Testing
- aprepitant, dexamethasone, ondansetron
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- OHSU Knight Cancer Institute
Hematologic Malignancy, Acute Myeloid Leukemia
T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies
This is a unique dose-escalation trial that will titrate doses of umbilical cord blood (UCB) Treg and CD3+ Teff cells with the goal of infusing as many CD3+ Teff cells as possible without conferring grade II-IV acute…
- Conditions
- Hematologic Malignancy, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia in Blast Crisis
- Trial name
- NCT01163201
- Testing
- Treg cells, CD3+ Teff cells, Fludarabine
- Where
- United States
- Sponsor
- Masonic Cancer Center, University of Minnesota
B Cell Precursor Acute Lymphoblastic Leukemia With Mixed Chimerism or Minimal Residual Disease After Allogeneic Stem Cell Transplantation, B-Cell Acute Lymphoblastic Leukemia
Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab
This phase 2 study is designed to evaluate the safety, tolerability and efficacy of allogeneic donor lymphocyte infusions (DLI) combined with the bispecific T cell engager blinatumomab in B-precursor ALL patients who have mixed…
- Conditions
- B Cell Precursor Acute Lymphoblastic Leukemia With Mixed Chimerism or Minimal Residual Disease After Allogeneic Stem Cell Transplantation, B-Cell Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia in Remission
- Trial name
- DLI-TARGET (NCT03982992)
- Testing
- Blinatumomab in combination with donor lymphocyte infusion
- Where
- Germany
- Sponsor
- Ludwig-Maximilians - University of Munich
Non-Hodgkin Lymphoma, B-cell, Acute Lymphoblastic Leukemia ALL
A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-cell Lymphoproliferative Disorders
This study is testing a new type of treatment called anti-CD19 CAR-T cell therapy for adults with certain blood cancers that have returned or did not respond to previous treatments.
- Trial name
- NCT06705530
- Testing
- Hem101
- Where
- Russia
- Volunteers
- 58 people
- Sponsor
- National Research Center for Hematology, Russia
Aggressive Non-Hodgkin Lymphoma, Blasts Under 5 Percent of Bone Marrow Nucleated Cells
Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies
This phase II trial studies how well donor atorvastatin treatment works in preventing severe graft-versus-host disease (GVHD) after nonmyeloablative peripheral blood stem cell (PBSC) transplant in patients with hematological…
- Conditions
- Aggressive Non-Hodgkin Lymphoma, Blasts Under 5 Percent of Bone Marrow Nucleated Cells, Chronic Lymphocytic Leukemia, Loss of Chromosome 17p
- Trial name
- NCT01527045
- Testing
- Atorvastatin Calcium, Cyclosporine, Fludarabine Phosphate
- Where
- 2 sites in United States
- Volunteers
- 47 people
- Sponsor
- Fred Hutchinson Cancer Center
B-cell Chronic Lymphocytic Leukemia, Nodal Marginal Zone B-cell Lymphoma
Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Monoclonal antibodies, such as yttrium Y 90 ibritumomab tiuxetan, can block find cancer cells and either kill them or carry cancer-killing substances to them without harming normal cells.
- Conditions
- B-cell Chronic Lymphocytic Leukemia, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma
- Trial name
- NCT00119392
- Testing
- rituximab, cyclosporine, fludarabine phosphate
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Fred Hutchinson Cancer Center
Acute Lymphoblastic Leukemia, Non-Hodgkin Lymphoma of Soft Tissue
A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies
A Study of Murine CD19 CAR-T Cells Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies.
- Trial name
- NCT04532281
- Testing
- Murine CD19 CAR-T cells
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Zhejiang University
Lymphoma, Prostate Cancer
Flavopiridol in Treating Patients With Refractory Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of flavopiridol in treating patients who have refractory…
- Conditions
- Lymphoma, Prostate Cancer, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00019344
- Testing
- alvocidib
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia
Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia
The combination of mitoxantrone and clofarabine as reinduction therapy will be safe, well tolerated and effective in children, adolescents and young adults with poor risk refractory/relapsed acute leukemia and high grade…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Lymphoblastic Lymphoma, Diffuse Large B-cell Lymphoma
- Trial name
- MITCL (NCT01842672)
- Testing
- Clofarabine, Mitoxantrone
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- New York Medical College
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia
NK Cells in Cord Blood Transplantation
This phase I trial studies the side effects and best way to give natural killer cells and donor umbilical cord blood transplant in treating patients with hematological malignancies.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission
- Trial name
- NCT01619761
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.